Objective:  The aim of this study was to report the use casirivimab/imdevimab therapy in pregnant women with moderate coronavirus disease 2019 (COVID-19). Study design:  We report 12 cases of unvaccinated pregnant patients with mild-to-moderate COVID-19 treated with casirivimab/imdevimab. Results:  Twelve unvaccinated pregnant patients with mild-to-moderate COVID-19 received casirivimab/imdevimab at the dose of 1200/1200 mg by intravenous infusion over 60 minutes. All women were managed outpatient. None experienced severe adverse drug reaction and none progressed to severe disease. Conclusion:  Casirivimab/imdevimab should be considered for outpatient treatment of unvaccinated pregnant women with mild-to-moderate COVID-19 to decrease the risk of severe disease. Key points: · Casirivimab/imdevimab is not well studied in pregnant women.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 decreases the risk of severe disease.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 is well tolerated..

Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019 / Buonomo, Antonio Riccardo; Filippo, Isabella Di; Esposito, Nunzia; Saccone, Gabriele; Nobile, Mariano; Viceconte, Giulio; Villari, Riccardo; Carlo, Costantino Di; Bifulco, Giuseppe; Gentile, Ivan. - In: AMERICAN JOURNAL OF PERINATOLOGY. - ISSN 0735-1631. - (2023). [10.1055/s-0042-1753488]

Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019

Buonomo, Antonio Riccardo;Filippo, Isabella Di;Esposito, Nunzia;Saccone, Gabriele;Nobile, Mariano;Viceconte, Giulio;Villari, Riccardo;Carlo, Costantino Di;Bifulco, Giuseppe;Gentile, Ivan
2023

Abstract

Objective:  The aim of this study was to report the use casirivimab/imdevimab therapy in pregnant women with moderate coronavirus disease 2019 (COVID-19). Study design:  We report 12 cases of unvaccinated pregnant patients with mild-to-moderate COVID-19 treated with casirivimab/imdevimab. Results:  Twelve unvaccinated pregnant patients with mild-to-moderate COVID-19 received casirivimab/imdevimab at the dose of 1200/1200 mg by intravenous infusion over 60 minutes. All women were managed outpatient. None experienced severe adverse drug reaction and none progressed to severe disease. Conclusion:  Casirivimab/imdevimab should be considered for outpatient treatment of unvaccinated pregnant women with mild-to-moderate COVID-19 to decrease the risk of severe disease. Key points: · Casirivimab/imdevimab is not well studied in pregnant women.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 decreases the risk of severe disease.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 is well tolerated..
2023
Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019 / Buonomo, Antonio Riccardo; Filippo, Isabella Di; Esposito, Nunzia; Saccone, Gabriele; Nobile, Mariano; Viceconte, Giulio; Villari, Riccardo; Carlo, Costantino Di; Bifulco, Giuseppe; Gentile, Ivan. - In: AMERICAN JOURNAL OF PERINATOLOGY. - ISSN 0735-1631. - (2023). [10.1055/s-0042-1753488]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/932051
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact